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Sir, 26 
The increasing rates of gut colonization by extended-spectrum cephalosporin-resistant (ESC-R-) 27 
and/or colistin-resistant Enterobacteriaceae (COL-R-Ent) carrying the plasmid-mediated mcr-1 28 
gene in healthy humans raises serious concerns [1, 2]. Nevertheless, colonization prevalence and 29 
risk factors associated with HIV+ individuals are unknown. This population undergoes a decrease 30 
in CD4+ T cells in the gut-associated lymphoid tissue which is linked with a microbiota dysbiosis 31 
possibly favoring colonization [3]. The aim of this pilot study was to better understand this 32 
phenomenon to improve the management of these patients. 33 
Between March 2015 and April 2016, 101 HIV+ individuals on suppressive anti-retroviral 34 
therapy (ART) donated a stool sample and filled out a questionnaire (Table S1 and S2). To detect 35 
ESC-R-, carbapenem-, and/or COL-R-Ent, stools were enriched in broth and plated on selective 36 
agar plates [1, 2]. Species identification was achieved by using the MALDI-TOF MS (Bruker 37 
Daltonics, Leipzig, Germany). MICs were obtained using the SentitreTM GNX2F plate (Trek 38 
Diagnostic Systems, Independence, OH, USA). β-lactamase genes were identified using both 39 
CT103XL microarray (Check-Points, Wageningen, Netherlands) and PCR/sequencing [1, 2]. COL-40 
R-Ent were screened for mcr-1/2 and PmrAB two-component system with PCR/sequencing [1]. 41 
Whole genome sequencing was carried out with MinION (Oxford Nanopore, Oxford, UK) [1]. 42 
Clonality was assessed with standard MLST (http://mlst.ucc.ie/mlst/dbs/Ecoli) and phylogenetic 43 
grouping [2]. The PBRT kit (Diatheva, Cartoceto, Italy) was used to type plasmids. Conjugation 44 
was performed using E. coli JF33 [1]. Univariate analysis was performed to compare colonized and 45 
non-colonized subjects (GraphPad Prism software, version 7.0; La Jolla, CA, USA). Continuous 46 
variables were analyzed using Mann–Whitney U test, whereas categorical variables with Fisher's 47 
exact test.  48 
Seven volunteers (6.9%) resulted colonized with ESC-R E. coli (other Enterobacteriaceae were 49 
not detected). This data is consistent with that reported in the healthy population in Switzerland and 50 
in other European countries [1, 2]. However, when looking into Enterobacteriaceae causing 51 
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infections in HIV+ subjects, the prevalence of ESC-R-Ent dramatically increased to 50%, though 52 
these studies were either conducted in countries with high occurrence of these multidrug-resistant 53 
organisms (MDROs) or have enrolled individuals not under ART [4 , 5]. 54 
Most ESC-R E. coli recovered in the present study were CTX-M-15 producers and associated with 55 
F plasmids (Table 1) [2]. Each isolate yielded an individual sequence type (ST), including the high 56 
risk clones (HiRC) ST131, ST73, ST405 and ST410 that might be associated with the frequent 57 
contact of HIV+ people with the healthcare facilities [2].  58 
Four volunteers (4.0%) were also colonized with COL-R E. coli (other Enterobacteriaceae 59 
were not detected), of which one (31349) was of B1-ST5 and mcr-1-positive. The remaining three 60 
strains failed to demonstrate a plasmid-mediated mechanism of colistin resistance after conjugation 61 
experiments [1]. Analysis of the PmrAB system indicated that these strains had amino acid 62 
substitutions possibly driving colistin resistance (Table 1) [1]. Demographic, clinical and 63 
epidemiological data about the four volunteers colonized with COL-R E. coli are shown in Table 64 
S1. Notably, volunteer 31349 was a 58 year-old male who in the last year was hospitalized in 65 
Switzerland and received antibiotics, but he did not traveled anywhere.  66 
Screening of raw genome data by PlasmidFinder-1.3 and ResFinder-2.1 indicated that E. coli strain 67 
31349 possessed IncF, IncL, and IncX4 plasmids together with the mcr-1 (no other resistance genes 68 
were detected) [1]. Mcr-1 was located in a 33.3 Kb plasmid that shared >99% identity (≤30 69 
mismatches) with IncX4 plasmids reported in E. coli from pig faeces in China (GenBank: 70 
KX254343) and from river water in Switzerland (GenBank: KZ129783). This is the first report of 71 
mcr-1-carrying Enterobacteriaceae in the gut of HIV+ people and highlights the global 72 
dissemination of this life-threatening resistance mechanism [1]. Despite the fact this COL-R strain 73 
carrying mcr-1 was pan-susceptible to all antibiotics, the detection of this gene in a population 74 
carrying ESBL-producing HiRC is of great concern because these MDROs can further acquire the 75 
mcr-1 and disseminate across different settings. 76 
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Regarding the univariate analysis, only the total CD4 cells count at the time of stool sampling 77 
was significantly lower among the colonized than those non-colonized subjects (median 301 vs. 706 78 
cells/µl; P=0.02; Table S2 and Figure S1). This observation may have important implications for 79 
empirical therapy when HIV+ individuals have serious bacterial infections. However, given the 80 
small sample size, our study lacks statistical power. This hinders meaningful multivariable analysis 81 
and potentially other associations in the univariate analysis. Additionally, it is possible that our 82 
results are representative only for a country (Switzerland) with low-prevalence of ESC-R E. coli 83 
colonization in the general population alongside HIV+ people under successful ART. Finally, as 84 
already reported in the general population, travelling to South-East Asia (P=0.07) and 85 
hospitalization abroad (P=0.13) could also be potentially correlated with ESC-R-Ent colonization 86 
[1, 2]. It is important to note that we were unable to include a control group due to the lack of 87 
information about HIV status and CD4 cell count of healthy people. 88 
This is the first study analyzing the presence of MDR Enterobacteriaceae in the intestinal tract 89 
of HIV+ people. When under ART, these subjects seem to acquire such pathogens as likely as the 90 
general population. However, the identification of HiRC underlines the potential for developing 91 
future difficult-to-treat extra-intestinal infections. Moreover, the identification of a strain carrying 92 
mcr-1 on a plasmid with high similarity with others present in food animals and environment 93 
highlights potential sources of acquisition of these pathogens. Finally, a low total CD4 count might 94 
be an additional risk factor favoring intestinal colonization. Elucidating this phenomenon with a 95 
larger cohort will be crucial for a better management of HIV+ patients.   96 
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